Fmr LLC Purchases 3,442 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Fmr LLC grew its position in Royalty Pharma plc (NASDAQ:RPRX) by 0.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 27,890,143 shares of the biopharmaceutical company’s stock after acquiring an additional 3,442 shares during the period. Fmr LLC owned 4.70% of Royalty Pharma worth $789,012,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Versant Capital Management Inc raised its position in Royalty Pharma by 5,215.0% during the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares during the last quarter. Gladius Capital Management LP bought a new position in Royalty Pharma during the 2nd quarter worth $32,000. Blue Trust Inc. raised its position in Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the last quarter. Finally, iA Global Asset Management Inc. raised its position in Royalty Pharma by 274.7% during the 2nd quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 4,683 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $26.60 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $27.19 and a two-hundred day moving average price of $27.35. Royalty Pharma plc has a 1-year low of $25.10 and a 1-year high of $31.66. The company has a market cap of $15.67 billion, a P/E ratio of 13.78, a PEG ratio of 4.65 and a beta of 0.47.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 annualized dividend and a dividend yield of 3.16%. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Analysts Set New Price Targets

Several brokerages recently issued reports on RPRX. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Citigroup lowered their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group increased their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.